-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, Xianju Pharmaceutical issued an announcement stating that it had recently received a notice of acceptance of the consistency evaluation of dexamethasone sodium phosphate injection issued by the State Food and Drug Administration.
It is reported that Dexamethasone Sodium Phosphate Injection was first developed by MERCK and was approved by the FDA in 1959.
According to the announcement, the approval numbers of Xianju Pharmaceutical Dexamethasone Sodium Phosphate Injection 1ml:2mg and 1ml:5mg are respectively: National Medicine Standard H33021095, National Medicine Standard H33020827, the current product implementation standard "Chinese Pharmacopoeia" 2020 edition two.